Loading…
United StatesSaved
The June 22–23, 2027 hybrid symposium at NYU Langone moves from immunometabolism and immune engineering to aging, leukemia and a panel on survivor partnerships. Registration rates vary by attendee category and format; abstract submissions are due April 13.
All times are local to the venue · America/New York
Survivor partnerships share the program with questions about engineered immunity at Frontiers in Cancer Immunotherapy. Across two days, the 14th-year symposium links research on resistance and immune response with clinical translation, poster sessions and a panel about survivors’ roles in research, media and funding.
The June 22 opening keynote gives the symposium an early focus on prevention and recurrence: Elizabeth Jaffee of Johns Hopkins Medicine is scheduled to speak about mobilizing T cells against premalignancy and malignancy recurrence. The following session approaches immune response through three different subjects: Jeffrey Rathmell on heat and immunity in tumors, Greg Delgoffe on metabolic barriers in cancer, and Ananda Goldrath on T-cell responses to infection and tumors across space and time.
That grouping makes the program’s interest in resistance more specific than a single therapeutic question. The speakers’ listed topics point to conditions in the tumor environment, immune metabolism and the contexts in which T cells respond. The event describes its wider scope as including emerging therapies, in-vivo immune engineering, aging and immune dysfunction, and cell therapy for acute myeloid leukemia (AML).
Further reading: Frontiers In Cancer Immunotherapy - NYAS ↗ · Agenda: Frontiers In Cancer Immunotherapy ↗
The first day places short talks selected from abstracts before a lunch-and-poster session, then turns to in-vivo immune engineering. Two speaker slots in that session are still to be announced; Justin Eyquem of the University of California, San Francisco, is also listed, without a talk title. Abstract presenters are considered for a slot rather than assured one.
The day’s translational session connects early-stage clinical trials to research questions. Thomas Marron of the Icahn School of Medicine at Mount Sinai is scheduled to discuss how trial findings can inform cancer immunology. He will also moderate a panel on survivor partnerships and their role in research, media and funding. The named panelists are Kristen Dahlgren of the Parker Institute for Cancer Immunotherapy and Jennifer K. Loukissas, MPP, of the National Cancer Institute; other panelists remain to be announced.
Networking breaks and a second lunch-and-poster period give the two days space for exchange outside the named talks. On Tuesday, abstract-selected presentations precede the poster lunch; on Wednesday, brief industry updates come before the poster lunch and the afternoon sessions. Those different formats are part of the event’s research program, not a separate public-facing activity lineup.
Further reading: Agenda: Frontiers In Cancer Immunotherapy ↗ · Frontiers In Cancer Immunotherapy ↗
Bernard Fox of Providence Cancer Institute is named for the June 23 opening keynote, though the agenda gives no talk title. The subsequent spatial-biology session includes Brian Brown of the Icahn School of Medicine at Mount Sinai on gene-to-cell crosstalk in tumor-microenvironment control. Jennifer Guerriero is listed without a talk title, followed by Caius Radu of UCLA on a programmable RNA-lipid nanoparticle platform for cancer vaccines.
The afternoon connects three distinct subjects under inflammation, aging and immune dysfunction: Ross Levine of Memorial Sloan Kettering Cancer Center on clonal hematopoiesis and solid-tumor biology and treatment response; Vishwa Deep Dixit of Yale University on “Inflammaging Checkpoints”; and Daniel Zabransky of Johns Hopkins Medicine on how aging shapes antitumor immunity in pancreatic cancer.
The final scientific session is devoted to cell therapy for AML. Iannis Aifantis of NYU Langone Health is scheduled to discuss the geography of immune responses in acute leukemia. Brian Betts of Roswell Park Comprehensive Cancer Center is also listed, without a talk title, and a third speaker is still to be announced. Crystal Mackall of Stanford Medicine is named for the closing keynote; the agenda does not provide its subject.
Further reading: Agenda: Frontiers In Cancer Immunotherapy ↗ · Speakers: Frontiers In Cancer Immunotherapy ↗
Two morning-session entries are printed with PM times: Ananda Goldrath is listed at 11:25 PM on June 22 within a session scheduled from 10:25 to 11:55 AM, and Caius Radu is listed at 11:15 PM on June 23 within a session scheduled from 10:15 to 11:45 AM. These are the agenda’s printed times; check with the organizer rather than assuming they mean AM.
The agenda also lists June 22 closing remarks at 5:10 PM while the translational session runs through 5:15 PM. On June 23, closing remarks at 5:25 PM fall within a closing keynote scheduled through 5:30 PM. The event’s daily window is 8:30 AM–5:30 PM ET, so confirm the latest agenda if a particular talk time or departure matters.
Further reading: Agenda: Frontiers In Cancer Immunotherapy ↗ · Frontiers In Cancer Immunotherapy ↗
The agenda moves from immunometabolism and in-vivo engineering toward clinical translation on day one, then turns to spatial biology, aging and AML on day two. Alongside keynotes and scientific sessions, it includes selected abstract talks, poster lunches, industry updates and networking breaks.
The event listing gives hours of 8:30 AM–5:30 PM ET each day. Check-in and breakfast are scheduled from 8:30 AM both mornings.
Frontiers In Cancer Immunotherapy ↗ · Agenda: Frontiers In Cancer Immunotherapy ↗
The symposium is listed as a hybrid event. The event information does not specify the virtual platform, access instructions or whether recordings will be available; confirm virtual arrangements during registration.
Frontiers In Cancer Immunotherapy - NYAS ↗ · Frontiers In Cancer Immunotherapy ↗
Published in-person / virtual rates are: Member, $455 / $160; Nonmember: Academia & Nonprofit, $570 / $200; Member: Student, Postdoc & Fellow, $180 / $65; Nonmember: Student, Postdoc, & Fellow, $230 / $80; and Nonmember: General Entry & Corporate, $680 / $240.
Registration is open. The event information does not state what each rate includes or give cancellation, transfer or refund terms.
Frontiers In Cancer Immunotherapy ↗ · Frontiers In Cancer Immunotherapy - NYAS ↗
Researchers at all levels, across disciplines and sectors, may submit work for consideration for a short talk or poster. Abstracts must relate to the symposium’s scientific topic and include primary scientific data. The limit is 1,500 characters, including spaces but excluding the title and affiliations; each presenter may submit one abstract. Selection is not guaranteed, and the organizer says early-career investigators will be included in talk and poster opportunities when feasible. The submission form also asks whether the presenter is within 10 years of receiving their final degree.
The submission form calls for a Title Case title and author names in first-name, last-name and middle-initial format; degree abbreviations should omit periods. Affiliations should list institution, city, state if applicable, and country, with state names written out. Multiple affiliations are separated by semicolons and numbered in brackets to match authors; for an author with multiple affiliations, the bracketed numbers follow the degree. The form also asks submitters to spell out special abbreviations on first use and spell special characters where possible.
Frontiers In Cancer Immunotherapy ↗ · Agenda: Frontiers In Cancer Immunotherapy ↗ · Frontiers In Cancer Immunotherapy ↗
The event planner is Sanaz Masserat, and the listed contact email is [email protected]. Cassie Chartier, PhD, is named as lead scientific planner.
The event is listed at NYU Langone, 550 1st Avenue, New York, NY 10016. The listing does not identify the event building, room or entrance. Map links can calculate directions from your starting point; the event information does not specify transit, parking or accessibility arrangements.
Yes. The event is listed as hybrid and publishes a separate virtual rate for each attendee category. The event information does not specify the online platform, access instructions or recording availability.
Frontiers In Cancer Immunotherapy - NYAS ↗ · Frontiers In Cancer Immunotherapy ↗
No. Submissions are for consideration for a short talk or poster, and the organizer says early-career investigators will be included when feasible.
Frontiers In Cancer Immunotherapy ↗ · Agenda: Frontiers In Cancer Immunotherapy ↗ · Frontiers In Cancer Immunotherapy ↗
550 1st Avenue, New York, NY 10016
Map search by venue and address. Check the organiser’s entrance details before travelling.
Images from the linked sources. Each caption identifies the context of the image.
Event, planning and background information checked 2026-11-03 against the linked sources.